252 related articles for article (PubMed ID: 16368883)
21. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
22. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
[TBL] [Abstract][Full Text] [Related]
23. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.
Schlenk RF; Kayser S; Bullinger L; Kobbe G; Casper J; Ringhoffer M; Held G; Brossart P; Lübbert M; Salih HR; Kindler T; Horst HA; Wulf G; Nachbaur D; Götze K; Lamparter A; Paschka P; Gaidzik VI; Teleanu V; Späth D; Benner A; Krauter J; Ganser A; Döhner H; Döhner K;
Blood; 2014 Nov; 124(23):3441-9. PubMed ID: 25270908
[TBL] [Abstract][Full Text] [Related]
24. Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia.
Yunus NM; Johan MF; Ali Nagi Al-Jamal H; Husin A; Hussein AR; Hassan R
Asian Pac J Cancer Prev; 2015; 16(12):4869-72. PubMed ID: 26163606
[TBL] [Abstract][Full Text] [Related]
25. De novo adult acute myeloid leukemia with two new mutations in juxtatransmembrane domain of the FLT3 gene: a case report.
Alarbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Liehr T; Aboukhamis I
J Med Case Rep; 2021 Jan; 15(1):22. PubMed ID: 33494808
[TBL] [Abstract][Full Text] [Related]
26. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
[TBL] [Abstract][Full Text] [Related]
27. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker FG; Du L; Luck TJ; Benner A; Krzykalla J; Gathmann I; Voso MT; Amadori S; Prior TW; Brandwein JM; Appelbaum FR; Medeiros BC; Tallman MS; Savoie L; Sierra J; Pallaud C; Sanz MA; Jansen JH; Niederwieser D; Fischer T; Ehninger G; Heuser M; Ganser A; Bullinger L; Larson RA; Bloomfield CD; Stone RM; Döhner H; Thiede C; Döhner K
Leukemia; 2022 Jan; 36(1):90-99. PubMed ID: 34316017
[TBL] [Abstract][Full Text] [Related]
28. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
30. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
[TBL] [Abstract][Full Text] [Related]
31. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.
Sengsayadeth SM; Jagasia M; Engelhardt BG; Kassim A; Strickland SA; Goodman S; Lucid C; Vnencak-Jones CL; Greer JP; Savani BN
Bone Marrow Transplant; 2012 Dec; 47(12):1535-7. PubMed ID: 22659680
[TBL] [Abstract][Full Text] [Related]
32. Structural and numerical variation of FLT3/ITD in pediatric AML.
Meshinchi S; Stirewalt DL; Alonzo TA; Boggon TJ; Gerbing RB; Rocnik JL; Lange BJ; Gilliland DG; Radich JP
Blood; 2008 May; 111(10):4930-3. PubMed ID: 18305215
[TBL] [Abstract][Full Text] [Related]
33. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
34. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
[TBL] [Abstract][Full Text] [Related]
35. Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia.
Govedarovic N; Marjanovic G
J BUON; 2011; 16(1):108-11. PubMed ID: 21674859
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD+) in de novo acute myeloid leukemia patients categorized according to cytogenetic risk.
Krum EA; Yamamoto M; Chauffaille Mde L
Sao Paulo Med J; 2009 Jan; 127(1):23-7. PubMed ID: 19466291
[TBL] [Abstract][Full Text] [Related]
37. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
[TBL] [Abstract][Full Text] [Related]
38. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
40. BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype.
Nasiłowska-Adamska B; Warzocha K; Solarska I; Borg K; Pieńkowska-Grela B; Czyż A
Eur J Haematol; 2017 Sep; 99(3):255-261. PubMed ID: 28618074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
